CareRx (CRRX) Q3 2024 earnings summary

Executive summary

• Achieved fifth consecutive quarter of Adjusted EBITDA growth, driven by operational efficiencies, improved supply terms, and strategic initiatives focused on operational excellence and lean principles.

• Modernized operating platform, reduced net debt, and implemented cost-saving measures to position for long-term growth in the seniors care sector.

• Announced new state-of-the-art fulfillment center in North Burnaby, BC, to consolidate operations and enhance service and efficiency.

• Appointment of Suzanne Brand as CFO, bringing extensive industry experience and expertise in growth and efficiency.

Financial highlights

• Q3 2024 revenue was $92.8 million, down from $93.8 million year-over-year but up from $92.0 million sequentially, reflecting a net reduction in average beds serviced offset by higher branded pharmaceutical prices.

• Adjusted EBITDA grew to $7.8 million, up 6.2% year-over-year and 3.4% sequentially, with margin rising to 8.4%.

• Net loss narrowed to $0.4 million in Q3 2024 from $1.4 million in both Q2 2024 and Q3 2023, mainly due to cost savings and lower finance costs.

• Cash balance at quarter-end was $8.8 million, up from $7.2 million last quarter; net debt reduced to $38.3 million.

• Cash provided by operations was $12.2 million in Q3 2024, up from $8.2 million in Q3 2023.

Outlook and guidance

• Targeting double-digit adjusted EBITDA margins for early 2025, supported by operational consolidation and efficiency gains.

• Nearly 3,000 new beds secured for onboarding in 2025, pending regulatory approvals, supporting expectations for continued expansion.

• Robust pipeline and enhanced operating platform expected to drive continued growth, with visibility into new long-term care bed additions and RFP wins.

• Focus on organic bed wins, M&A, and expanded services to sustain profitable growth.